Cargando…

Delayed adverse events in phase I trials of molecularly targeted and cytotoxic agents

BACKGROUND: Grade 3 and 4 adverse events (AEs) during cycle 1 are traditionally used for dose escalation decisions in Phase I oncology trials. With molecularly targeted agents (MTAs), assessment of lower grade AEs and those in later cycles is considered increasingly relevant. METHODS: We conducted a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jordan, Emma J., Spicer, James, Sarker, Debashis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2018
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6188052/ https://www.ncbi.nlm.nih.gov/pubmed/30338038 http://dx.doi.org/10.18632/oncotarget.26104

Ejemplares similares

Revitalising cancer trials post-pandemic: time for reform
por: Morton, Cienne, et al.
Publicado: (2023)

Phase I clinical trial repurposing all-trans retinoic acid as a stromal targeting agent for pancreatic cancer
por: Kocher, Hemant M., et al.
Publicado: (2020)

Creatinine Clearance Is Associated with Toxicity from Molecularly Targeted Agents in Phase I Trials
por: Basu, B., et al.
Publicado: (2012)

Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent
por: Lickliter, J D, et al.
Publicado: (2010)

Clinical benefit in Phase-I trials of novel molecularly targeted agents: does dose matter?
por: Postel-Vinay, S, et al.
Publicado: (2009)

Fatal adverse events with molecular targeted agents in the treatment of advanced hepatocellular carcinoma: a meta-analysis of randomized controlled trials
por: Li, Xiaofei, et al.
Publicado: (2018)

Modern dose-finding designs for cancer phase I trials: drug combinations and molecularly targeted agents
por: Hirakawa, Akihiro, et al.
Publicado: (2018)

Efficiency of New Dose Escalation Designs in Dose-Finding Phase I Trials of Molecularly Targeted Agents
por: Le Tourneau, Christophe, et al.
Publicado: (2012)

Comparison of prognostic factors in patients in phase I trials of cytotoxic drugs vs new noncytotoxic agents
por: Han, C, et al.
Publicado: (2003)

A phase I study to assess afatinib in combination with carboplatin or with carboplatin plus paclitaxel in patients with advanced solid tumors
por: O’Brien, Mary E. R., et al.
Publicado: (2018)

Patient-reported tolerability of adverse events in phase 1 trials
por: Henon, Clémence, et al.
Publicado: (2017)

Pragmatic dose-escalation methods incorporating relative dose intensity assessment for molecularly targeted agents in phase I trials
por: Hirakawa, Akihiro, et al.
Publicado: (2019)

Precision Medicine for Molecularly Targeted Agents and Immunotherapies in Early-Phase Clinical Trials
por: Lopez, Juanita, et al.
Publicado: (2015)

Challenges and Innovations in Phase I Dose-Finding Designs for Molecularly Targeted Agents and Cancer Immunotherapies
por: Yin, Jun, et al.
Publicado: (2016)

Phase I trials of antitumour agents: fundamental concepts
por: Toloi, Diego de Araujo, et al.
Publicado: (2015)

Treatment-related severe and fatal adverse events with molecular targeted agents in the treatment of advanced gastric cancer: a meta-analysis
por: Wang, Liang, et al.
Publicado: (2017)

Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials
por: Yokota, Tomoya, et al.
Publicado: (2018)

An information theoretic phase I–II design for molecularly targeted agents that does not require an assumption of monotonicity
por: Mozgunov, Pavel, et al.
Publicado: (2018)

Synthesis, molecular docking, and cytotoxicity of quinazolinone and dihydroquinazolinone derivatives as cytotoxic agents
por: Taayoshi, Fahimeh, et al.
Publicado: (2022)

Overlap between adverse events (AEs) and serious adverse events (SAEs): a case study of a phase III cancer clinical trial
por: James, Elizabeth C., et al.
Publicado: (2020)

Factors Related to Delayed Adverse Events of Endoscopic Submucosal Dissection in the Duodenum
por: Kawamura, Tatsuya, et al.
Publicado: (2023)

Exploring Adverse Events and Utilization of Topical Hemostatic Agents in Surgery
por: O’Hanlan, Katherine A., et al.
Publicado: (2022)

Psychiatric adverse events in three phase III trials of eslicarbazepine acetate for focal seizures
por: Altalib, Hamada, et al.
Publicado: (2022)

Simultaneous Pseudoprogression and an Immune-related Adverse Event of Pulmonary Pleomorphic Carcinoma after Combined Therapy with Cytotoxic Anticancer Agents and Immune Checkpoint Inhibitor
por: Murao, Koutaro, et al.
Publicado: (2022)

A Road Map for Designing Phase I Clinical Trials of Radiotherapy–Novel Agent Combinations
por: Brown, Sarah R., et al.
Publicado: (2022)

Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studies
por: Mandalà, M, et al.
Publicado: (2012)

Molecular Delivery of Cytotoxic Agents via Integrin Activation
por: Cirillo, Martina, et al.
Publicado: (2021)

Challenges in Coding Adverse Events in Clinical Trials: A Systematic Review
por: Schroll, Jeppe Bennekou, et al.
Publicado: (2012)

Prognostic and predictive factors associated with ipilimumab-related adverse events: a retrospective analysis of 11 NCI-sponsored phase I clinical trials
por: Chauhan, Aman, et al.
Publicado: (2020)

Delayed Adverse Events after Procedural Sedation in Pediatric Patients with Hematologic Malignancies
por: Joo, Jin, et al.
Publicado: (2022)

Adverse events are not increased by controlled delay in surgery of acute upper extremity fractures
por: Matias, Torkki, et al.
Publicado: (2023)

Cytotoxic Proteins and Therapeutic Targets in Severe Cutaneous Adverse Reactions
por: Su, Shih-Chi, et al.
Publicado: (2014)

Quantification of Pancreatic Cancer Proteome and Phosphorylome: Indicates Molecular Events Likely Contributing to Cancer and Activity of Drug Targets
por: Britton, David, et al.
Publicado: (2014)

CYTOTOXICITY MEDIATED BY SOLUBLE ANTIGEN AND LYMPHOCYTES IN DELAYED HYPERSENSITIVITY : I. CHARACTERIZATION OF THE PHENOMENON
por: Ruddle, Nancy H., et al.
Publicado: (1968)

Heterogeneous treatment effects of intensive glycemic control on major adverse cardiovascular events in the ACCORD and VADT trials: a machine-learning analysis
por: Edward, Justin A., et al.
Publicado: (2022)

Association of creatine kinase and skin toxicity in phase I trials of anticancer agents
por: Moreno Garcia, V, et al.
Publicado: (2012)

Effects of cytotoxic agents on TdR incorporation and growth delay in human colonic tumour xenografts.
por: Houghton, P. J., et al.
Publicado: (1977)

Mitigating long-term and delayed adverse events associated with cancer treatment: implications for survivorship
por: Lustberg, Maryam B., et al.
Publicado: (2023)

Issues Impacting Adverse Event Frequency and Severity: Differences Between Randomized Phase 2 and Phase 3 Clinical Trials for Lasmiditan
por: Kudrow, David, et al.
Publicado: (2020)

Adverse Event Profiles of Platinum Agents: Data Mining of the Public Version of the FDA Adverse Event Reporting System, AERS, and Reproducibility of Clinical Observations
por: Sakaeda, Toshiyuki, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_ic0ng15usgnrn6e3uh66t5iqvd